Key Points
- Septerna insider Samira Shaikhly sold 5,935 shares on June 1 at an average price of $28.93, for total proceeds of about $171,700. After the sale, Shaikhly’s direct ownership fell to 793 shares, an 88.21% decrease in the position.
- Shaikhly also sold 11,798 shares on May 26 at an average price of $30.06, bringing in about $354,648. The two transactions highlight notable recent insider selling at the biotech company.
- Septerna’s stock was up 2.0% and opened at $30.55, near its 52-week high of $32.63. The company recently beat quarterly EPS and revenue expectations, while analysts currently rate the stock a Moderate Buy with a consensus target price of $43.13.
Septerna, Inc. (NASDAQ:SEPN - Get Free Report) insider Samira Shaikhly sold 5,935 shares of the company's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $28.93, for a total value of $171,699.55. Following the transaction, the insider directly owned 793 shares in the company, valued at $22,941.49. This trade represents a 88.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Samira Shaikhly also recently made the following trade(s):
- On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The shares were sold at an average price of $30.06, for a total value of $354,647.88.
Septerna Stock Up 2.0%
Shares of SEPN stock opened at $30.55 on Thursday. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of -37.72 and a beta of 2.39. Septerna, Inc. has a 12 month low of $9.70 and a 12 month high of $32.63. The stock has a 50-day moving average price of $25.85 and a 200 day moving average price of $26.38.
Septerna (NASDAQ:SEPN - Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.23. The company had revenue of $26.52 million for the quarter, compared to the consensus estimate of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. Sell-side analysts predict that Septerna, Inc. will post -1.57 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Septerna
Hedge funds and other institutional investors have recently made changes to their positions in the company. Group One Trading LLC grew its holdings in shares of Septerna by 111.8% in the 4th quarter. Group One Trading LLC now owns 944 shares of the company's stock valued at $26,000 after buying an additional 8,955 shares during the period. Global Retirement Partners LLC bought a new position in Septerna during the fourth quarter worth about $35,000. Russell Investments Group Ltd. acquired a new position in Septerna in the third quarter valued at about $36,000. Caitong International Asset Management Co. Ltd acquired a new position in Septerna in the fourth quarter valued at about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Septerna in the fourth quarter worth about $61,000.
Analyst Upgrades and Downgrades
SEPN has been the topic of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Septerna in a research note on Wednesday, May 13th. Zacks Research upgraded shares of Septerna from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 24th. Wall Street Zen downgraded Septerna from a "buy" rating to a "hold" rating in a research note on Saturday, March 14th. Stifel Nicolaus started coverage on Septerna in a research note on Friday, May 1st. They set a "buy" rating and a $43.00 price objective for the company. Finally, Truist Financial upped their price objective on Septerna from $34.00 to $35.00 and gave the company a "buy" rating in a report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.13.
View Our Latest Stock Analysis on Septerna
Septerna Company Profile
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
